Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 45

Sort by

Sort Order Select

Journal Articles

Prognostic impact of cytogenetic abnormalities detected by FISH in AL amyloidosis with daratumumab-based frontline therapy

Rajshekhar Chakraborty, Saurabh Zanwar, Ute Hegenbart, Divaya Bhutani, Morie A. Gertz, Angela Dispenzieri, Shaji Kumar, Anita D’Souza, Anannya Patwari, Andrew Cowan, GuiZhen Chen, Paolo Milani, Giovanni Palladini, Vaishali Sanchorawala, Geethika Bodanapu, Stefan O. Schönland, Suzanne Lentzsch, Eli Muchtar

Blood (2024) 144 (25): 2613–2624.

https://doi.org/10.1182/blood.2024025899

Published: 2024

Includes: Supplemental data

Journal Articles

Flow Cytometry-Based Assessment of the Proportion of Monoclonal Plasma Cells in Synthetic Phase (S-phase) Is an Independent Marker of Adverse Prognosis in Patients with Newly Diagnosed Multiple Myeloma

Blood (2024) 144 (Supplement 1): 4704.

https://doi.org/10.1182/blood-2024-201052

Published: 2024

Journal Articles

Multi-Omics DNA Methylation Analysis of MYD88 Wild-Type Waldenstrom Macroglobulinemia Reveals Potential Epigenetic Influence on Oncogenic Pathways

Blood (2024) 144 (Supplement 1): 6201.

https://doi.org/10.1182/blood-2024-205509

Published: 2024

Journal Articles

Light Chain Multiple Myeloma - Clinical Characteristics and Outcomes

Blood (2024) 144 (Supplement 1): 6950.

https://doi.org/10.1182/blood-2024-208468

Published: 2024

Journal Articles

Development of a Risk Prediction Model for 6-Month Early Mortality in Patients with Systemic Light Chain Amyloidosis Treated with Daratumumab-Based Frontline Therapy

Blood (2024) 144 (Supplement 1): 287.

https://doi.org/10.1182/blood-2024-202589

Published: 2024

Journal Articles

Evaluating the Interaction between Baseline Risk Stratification, Post-Transplant Measurable Residual Disease, and Long-Term Outcomes in Multiple Myeloma

Blood (2024) 144 (Supplement 1): 4716.

https://doi.org/10.1182/blood-2024-211755

Published: 2024

Journal Articles

The Mutational Landscape of Extramedullary Multiple Myeloma Reveals Novel Biologic Insights and Potential Therapeutic Targets for Exploration

Saurabh Zanwar, Joseph Novak, Michael D Howe, Moritz Binder, Wilson I. Gonsalves, Esteban Braggio, Vincent Rajkumar, Dragan Jevremovic, Surendra Dasari, Shaji Kumar

Blood (2024) 144 (Supplement 1): 2744.

https://doi.org/10.1182/blood-2024-203350

Published: 2024

Journal Articles

Development of a Three-Gene-Based Proliferation Score (3GPS) to Predict Proliferation Index in Newly Diagnosed Multiple Myeloma

Arwa Bohra, Surendra Dasari, Wilson I. Gonsalves, Prashant Kapoor, Saurabh Zanwar, Moritz Binder, Angela Dispenzieri, Michael M Timm, Dragan Jevremovic, S. Vincent Rajkumar, Shaji Kumar

Blood (2024) 144 (Supplement 1): 1945.

https://doi.org/10.1182/blood-2024-211902

Published: 2024

Journal Articles

A Comparative Study of Plasma Cell Detection By Peripheral Smear and Peripheral Blood Flow Cytometry

Arwa Bohra, Rafla Hassan, Saurabh Zanwar, Dragan Jevremovic, Horatiu Olteanu, Wilson I. Gonsalves, Gregory Otteson, Pedro Horna, S. Vincent Rajkumar, Shaji Kumar

Blood (2024) 144 (Supplement 1): 3319.

https://doi.org/10.1182/blood-2024-211626

Published: 2024

Journal Articles

Post-CAR-T Driving Restrictions after Week 4 Appear Unnecessary: Data from the United States Myeloma Immunotherapy Consortium

Blood (2024) 144 (Supplement 1): 3765.

https://doi.org/10.1182/blood-2024-199609

Published: 2024

Journal Articles

Real World Outcomes with Venetoclax (Ven)-Based Therapies in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): A Mayo Clinic Comprehensive Cancer Center (MCCC) Experience

Blood (2024) 144 (Supplement 1): 1981.

https://doi.org/10.1182/blood-2024-208294

Published: 2024

Journal Articles

Outcomes of Venetoclax-Based Treatment Combinations in Relapsed/Refractory Multiple Myeloma: Real-World Practice Patterns and Impact of Cytogenetics on Outcomes

Blood (2024) 144 (Supplement 1): 4728.

https://doi.org/10.1182/blood-2024-208736

Published: 2024

Journal Articles

Efficacy of Small Molecule Kinase Inhibitors in Histiocytic Neoplasms with Non-BRAFV600E Mutations: Concordance of Pre-Clinical Predictions to Clinical Responses

Alanis Enid Rodriguez-Rosario, Aldo Adrian Acosta Medina, N. Nora Bennani, Gaurav Goyal, Aishwarya Ravindran, Karen L Rech, Gordon J Ruan, Mithun V Shah, Dongni Yi, Saurabh Zanwar, Jithma P Abeykoon, Ronald S Go

Blood (2024) 144 (Supplement 1): 4564.

https://doi.org/10.1182/blood-2024-205474

Published: 2024

Journal Articles

Presence of Circulating Tumor Cells on Peripheral Blood Flow Cytometry at Best Response Predicts Overall Survival in Multiple Myeloma

Arwa Bohra, Saurabh Zanwar, Dragan Jevremovic, Horatiu Olteanu, Wilson I. Gonsalves, Gregory Otteson, Pedro Horna, Vincent Rajkumar, Shaji Kumar

Blood (2024) 144 (Supplement 1): 3340.

https://doi.org/10.1182/blood-2024-212089

Published: 2024

Journal Articles

Efficacy of Targeted Agents and Immune Checkpoint Inhibitors in Patients with Malignant Histiocytosis

Blood (2024) 144 (Supplement 1): 4563.

https://doi.org/10.1182/blood-2024-204398

Published: 2024

Journal Articles

Outcomes of Patients with Relapsed/Refractory Lymphoplasmacytic Lymphoma Treated with Venetoclax: A Multicenter Retrospective Analysis

Blood (2023) 142 (Supplement 1): 3045.

https://doi.org/10.1182/blood-2023-187237

Published: 2023

Journal Articles

Modified Staging System for Waldenström Macroglobulinemia (MSS-WM): A Multi-Institutional Externally Validated Prognostic Model for Active/Symptomatic Waldenström Macroglobulinemia

Blood (2023) 142 (Supplement 1): 3030.

https://doi.org/10.1182/blood-2023-179940

Published: 2023

Journal Articles

Outcomes with MEK Inhibitor Therapy Among Adults with Langerhans Cell Histiocytosis (LCH): A Multi-Institutional Study from the Adult LCH Working Group for the Histiocyte Society

Blood (2023) 142 (Supplement 1): 4559.

https://doi.org/10.1182/blood-2023-184911

Published: 2023

Journal Articles

Factors Affecting Health-Related Quality of Life Among Individuals with Histiocytic Neoplasms

David Pottinger, Matthew Slief, Ene Enogela, Jithma Prasad Abeykoon, Saurabh Zanwar, Gordon J Ruan, Rachelle Rouse, Baylie Mullinax, Kathleen Brewer, Deanna Fournier, Aishwarya Ravindran, Diana Morlote, Samuel Hand, Maria D Acosta Lara, Richard Taylor, Abby McCrory, Anita D'Souza, Ronald S. Go, Gaurav Goyal

Blood (2023) 142 (Supplement 1): 6394.

https://doi.org/10.1182/blood-2023-178372

Published: 2023

Journal Articles

The Peripheral Blood Stem Cell Immunome Demonstrates Abnormal Immune Effector Cells Early in the Disease Course of Multiple Myeloma and Contributes to Inferior Outcomes and Secondary Myeloid Neoplasms

Saurabh Zanwar, Eapen K. Jacob, Carl Greiner, Kevin Pavelko, Michael Strausbauch, Emilie Anderson, Arini Arsana, Megan Weivoda, Mithun V Shah, Taxiarchis Kourelis

Blood (2023) 142 (Supplement 1): 90.

https://doi.org/10.1182/blood-2023-174286

Published: 2023

NARROW

Prognostic impact of cytogenetic abnormalities detected by FISH in AL amyloidosis with daratumumab-based frontline therapy

Flow Cytometry-Based Assessment of the Proportion of Monoclonal Plasma Cells in Synthetic Phase (S-phase) Is an Independent Marker of Adverse Prognosis in Patients with Newly Diagnosed Multiple Myeloma

Multi-Omics DNA Methylation Analysis of MYD88 Wild-Type Waldenstrom Macroglobulinemia Reveals Potential Epigenetic Influence on Oncogenic Pathways

Light Chain Multiple Myeloma - Clinical Characteristics and Outcomes

Development of a Risk Prediction Model for 6-Month Early Mortality in Patients with Systemic Light Chain Amyloidosis Treated with Daratumumab-Based Frontline Therapy

Evaluating the Interaction between Baseline Risk Stratification, Post-Transplant Measurable Residual Disease, and Long-Term Outcomes in Multiple Myeloma

The Mutational Landscape of Extramedullary Multiple Myeloma Reveals Novel Biologic Insights and Potential Therapeutic Targets for Exploration

Development of a Three-Gene-Based Proliferation Score (3GPS) to Predict Proliferation Index in Newly Diagnosed Multiple Myeloma

A Comparative Study of Plasma Cell Detection By Peripheral Smear and Peripheral Blood Flow Cytometry

Post-CAR-T Driving Restrictions after Week 4 Appear Unnecessary: Data from the United States Myeloma Immunotherapy Consortium

Real World Outcomes with Venetoclax (Ven)-Based Therapies in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): A Mayo Clinic Comprehensive Cancer Center (MCCC) Experience

Outcomes of Venetoclax-Based Treatment Combinations in Relapsed/Refractory Multiple Myeloma: Real-World Practice Patterns and Impact of Cytogenetics on Outcomes

Efficacy of Small Molecule Kinase Inhibitors in Histiocytic Neoplasms with Non-BRAFV600E Mutations: Concordance of Pre-Clinical Predictions to Clinical Responses

Presence of Circulating Tumor Cells on Peripheral Blood Flow Cytometry at Best Response Predicts Overall Survival in Multiple Myeloma

Efficacy of Targeted Agents and Immune Checkpoint Inhibitors in Patients with Malignant Histiocytosis

Outcomes of Patients with Relapsed/Refractory Lymphoplasmacytic Lymphoma Treated with Venetoclax: A Multicenter Retrospective Analysis

Modified Staging System for Waldenström Macroglobulinemia (MSS-WM): A Multi-Institutional Externally Validated Prognostic Model for Active/Symptomatic Waldenström Macroglobulinemia

Outcomes with MEK Inhibitor Therapy Among Adults with Langerhans Cell Histiocytosis (LCH): A Multi-Institutional Study from the Adult LCH Working Group for the Histiocyte Society

Factors Affecting Health-Related Quality of Life Among Individuals with Histiocytic Neoplasms

The Peripheral Blood Stem Cell Immunome Demonstrates Abnormal Immune Effector Cells Early in the Disease Course of Multiple Myeloma and Contributes to Inferior Outcomes and Secondary Myeloid Neoplasms

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only